Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04436718
Other study ID # 1374867-5
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 1, 2019
Est. completion date July 1, 2021

Study information

Verified date June 2020
Source Riverside University Health System Medical Center
Contact Michael Ulrich, MD
Phone 9514864640
Email m.ulrich@ruhealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates daily POCUS/FCU exams on patients admitted for acute decompensated heart failure with primary end point of acute kidney injury while in hospital.


Description:

Patients with admitted to hospital with Acute Decompensated Heart failure (ADHF) suffer a significant morbidity and premature mortality. Administration of intravenous (IV) diuretics is largely guided by clinical judgment based on physical exam, net fluid measurement, changes in daily weights and chest x-ray findings. The key objective is to promote adequate diuresis while improving symptoms, without compromising renal function. Laboratory tests demonstrating hemo-concentration, increasing BUN, and increasing creatinine have been proposed as positive prognostic indicators in patients receiving IV diuretic therapy but these methods suffer from inadequate predictive value. Observational studies have identified worsening renal failure (WRF) in patients admitted for heart failure as an important clinical entity associated with worsening clinical outcomes.

Point of care Ultrasound (POCUS) has the potential to fill an unmet need for monitoring patients recieving IV diuretic therapy. POCUS provides clinicians with immediate diagnostic information obtained and interpreted at bedside that can augment and enhance the physical examination. Numerous studies have examined POCUS assessment of pulmonary edema and measurement of the Inferior Vena Cava (IVC) to estimate hemodynamic parameters for patients with acute decompensated heart failure (ADHF). No study to date has examined POCUS effect on clinical outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date July 1, 2021
Est. primary completion date July 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 95 Years
Eligibility Inclusion Criteria:

- Age >18 admitted for acute decompensated heart failure exacerbation as primary admission diagnosis from Emergency department to General Medicine ward that are administered diuretic therapy expected to be admitted for two days or more.

Exclusion Criteria:

1. Decline consent for study

2. If admitted and research team not available for consent and initial evaluation prior within 6 hours of first diuretic administration

3. Patients in whom diuretics will not be utilized (i.e. anuric, ESRD on HD)

4. Inability to assess IVC (surgical anatomy, body habitus, Ileus, etc.)

5. Patients admitted to ICU

6. Patients currently on positive pressure ventilation (BiPAP)

7. Patients discharged from the emergency department

8. Patients discharged prior to evaluation by the POCUS team

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Daily pocus exam
Daily evaluation of lung ultrasound for B line artifacts plus IVC assessments

Locations

Country Name City State
United States RUHS Medical center Moreno Valley California

Sponsors (1)

Lead Sponsor Collaborator
Riverside University Health System Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Worsening renal failure Serum Creatnine levels measured in mg/dL During hospitalization typically one week
Secondary Length of stay Measured in days from initial admission to discharge During hospitalization typically one week
See also
  Status Clinical Trial Phase
Completed NCT04049045 - Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure Phase 2
Active, not recruiting NCT05100836 - SURPASS Impella 5.5 Study
Recruiting NCT02898181 - Low Level Tragus Stimulation in Acute Decompensated Heart Failure N/A
Completed NCT02823626 - High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
Completed NCT02196038 - A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients N/A
Completed NCT02248831 - Evaluation of Cardiopulmonary Diseases by Ultrasound N/A
Completed NCT00693745 - Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF N/A
Not yet recruiting NCT04391231 - HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial Phase 4
Recruiting NCT05206422 - DORAYA-HF Early Feasibility Study N/A
Recruiting NCT01960218 - Gas Exchange for Predicting Hospital Heart Failure Readmissions N/A
Terminated NCT00904488 - Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure Phase 4
Terminated NCT02620384 - Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study. Phase 3
Completed NCT04318093 - Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure Phase 2
Recruiting NCT06161649 - Mobile Education System to Improve Disease Knowledge, Self-efficacy and Quality of Life in Patients With Heart Failure N/A
Completed NCT02289508 - Role of USCOM in Adult Patients With Heart Failure N/A
Terminated NCT01457053 - Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics N/A
Completed NCT04877652 - DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
Completed NCT03505788 - Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) Phase 4
Completed NCT03146754 - A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE) N/A
Not yet recruiting NCT06414759 - Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload Phase 4